WEBULL
WebtradeDownload

Septerna (SEPN) Faces A Valuation Test Following Its New CMO Grant

Simply Wall St · 2d ago

Septerna (SEPN) has drawn fresh attention after granting a non qualified stock option for up to 275,000 shares to new Chief Medical Officer Dr. Rajiv Patni, tied to its 2026 Inducement Plan.

Septerna’s share price has pulled back over the past month, with a 30 day share price return of a 20.96% decline. However, the year to date share price return of 34.92% and 1 year total shareholder return of 161.79% point to strong positive momentum in the background.

Compare Septerna’s recent swing with a hand picked set of biotech and healthcare names by scanning 18 high quality undiscovered gems that are still flying under most investors’ radar.

The chart has snapped back hard, yet Septerna still trades below published analyst targets and carries ongoing losses. Does that mix leave more upside than downside, or has the easy money already been made?

Price to Sales of 17.8x: Is It Justified for Septerna?

Septerna trades on a P/S ratio of 17.8x, which is high compared with both its peer group and the broader US pharmaceuticals sector at the current $37.75 share price.

P/S looks at how much investors are paying for each dollar of revenue. For a clinical stage biotech like Septerna, this often reflects expectations around the pipeline and future commercialisation rather than current profitability, since the business is loss making and forecast to remain unprofitable over the next three years.

The current multiple significantly exceeds the estimated fair P/S ratio of 3.9x, which suggests the market price is rich relative to what the regression based fair ratio implies. The P/S of 17.8x is also much higher than both the US pharmaceuticals industry average of 5.3x and the peer average of 5.6x, pointing to a valuation that embeds far stronger expectations than those reference points.

Explore the SWS fair ratio for Septerna

Result: Price-to-Sales of 17.8x (OVERVALUED)

Still, Septerna faces clear pressure points, including annual revenue and net income declines, as well as the risk that its GPCR pipeline or Novo Nordisk collaboration underdelivers.

Find out about the key risks to this Septerna narrative.

Next Steps

Mixed signals on Septerna can leave even experienced investors split. Move quickly, review the underlying data, and weigh the trade off between 1 key reward and 3 important warning signs.

Looking for more Septerna sized opportunities?

Use the Simply Wall St screener to spot fresh ideas with different risk and reward profiles before they move out of reach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.